×
Acupuncture Reduced AI-Related Joint Pain in Early-Stage Breast Cancer
http://www.cancernetwork.com/sabcs/acupuncture-reduced-ai-related-joint-pain-early-stage-breast-cancer

Dec 7th, 2017 - Undergoing acupuncture significantly reduced joint pain related to treatment with aromatase inhibitors in postmenopausal women with early-stage breast cancer.

Acupuncture May Reduce Joint Pain Caused by Aromatase Inhibitor Treatment
http://www.ascopost.com/News/58329

Dec 7th, 2017 - Acupuncture significantly reduced joint pain for postmenopausal women with early-stage breast cancer receiving treatment with an aromatase inhibitor compared with both sham acupuncture and no treatment, according to data from the randomized, phase III SWOG S1200 trial presented by Hershman et al at the 2017 San Antonio Breast Cancer Symposium (Abstract GS4-04).

Acupuncture significantly reduces joint pain for breast cancer patients
https://ecancer.org/conference/966-sabcs-2017/news/12901-sabcs-2017--acupuncture-significantly-reduces-joint-pain-for-breast-cancer-patients.php

Dec 7th, 2017 - In the largest, most rigorous study of its kind, acupuncture was found to significantly reduce the debilitating joint pain experienced by tens of thousands of women each year while being treated for early stage breast cancer, according to SWOG research results to be announced at a December 7 press conference at the San Antonio Breast Cancer Symposium.

Acupuncture significantly reduces AI-associated arthralgias
https://www.mdedge.com/oncologypractice/article/153877/breast-cancer/acupuncture-significantly-reduces-ai-associated

Dec 8th, 2017 - Women receiving acupuncture had significantly lower joint pain scores in a randomized phase 3 trial.

Adjuvant trastuzumab for 1 year remains standard of care for early HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/153900/breast-cancer/adjuvant-trastuzumab-1-year-remains-standard-care

Dec 8th, 2017 - The phase 3 SOLD trial failed to show a 9 week course of trastuzumab as noninferior to the standard 12-month course.

Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-Low Breast Cancer
http://www.ascopost.com/News/58322

Dec 6th, 2017 - Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, defined as immunohistochemistry (IHC) 1–positive or IHC 2-positive and/or in situ hybridization (ISH)–negative, according to data from the randomized, phase III NSABP B-47 clinical trial presented by Fehrenb...

Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes
https://www.onclive.com/conference-coverage/sabcs-2017/alternative-chemotherapy-dosing-strategies-improve-breast-cancer-outcomes

Dec 6th, 2017 - Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

ALND Increases Arm Morbidity in Young Breast Cancer Patients
http://www.cancernetwork.com/sabcs/alnd-increases-arm-morbidity-young-breast-cancer-patients

Dec 18th, 2017 - Undergoing axillary lymph node dissection is associated with increased arm morbidity in younger breast cancer patients compared with sentinel lymph node biopsy.

Axillary node dissection can be avoided with limited SLN involvement
https://www.mdedge.com/oncologypractice/article/155143/breast-cancer/axillary-node-dissection-can-be-avoided-limited-sln

Dec 26th, 2017 - Axillary dissection can be avoided in patients with early breast cancer and limited sentinel node involvement, investigators reported at the San Antonio Breast Cancer Symposium.

Antibody-Drug Conjugate Active in Heavily Pretreated Metastatic TNBC
https://www.onclive.com/conference-coverage/sabcs-2017/antibodydrug-conjugate-active-in-heavily-pretreated-metastatic-tnbc

Dec 8th, 2017 - Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.

Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival
https://www.cancertherapyadvisor.com/sabcs-2017/breast-cancer-axillary-dissection-no-effect-long-term-survival/article/713097/

Dec 8th, 2017 - At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups.

Both Vinorelbine and Paclitaxel Reach Disease Control Rates of 75% in ER+, HER2-Negative Advanced Breast Cancer
https://www.practiceupdate.com/content/sabcs-2017-both-vinorelbine-and-paclitaxel-reach-disease-control-rates-of-75-in-er-her2-negative-advanced-breast-cancer/61147/62

Dec 10th, 2017 - Both oral vinorelbine and intravenous paclitaxel reached similar rates of disease control, 75%. Each regimen presented a specific tolerance profile. Oral vinorelbine was associated with a lower incidence of alopecia and peripheral neuropathy.

Cancer Blood Test Shows Promise
https://www.medpagetoday.com/meetingcoverage/sabcs/69784

Dec 8th, 2017 - A blood test for breast cancer cells can help predict who is likely to have a late recurrence of the disease and who is not, a researcher said here.

Can Temporary Ovarian Suppression During Breast Cancer Treatment Preserve Fertility?
http://www.cancernetwork.com/sabcs/can-temporary-ovarian-suppression-during-breast-cancer-treatment-preserve-fertility

Dec 7th, 2017 - Treatment with gonadotropin-releasing hormone analog can safely and effectively protect ovarian function and has the potential to preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.

CDK4/6 inhibitors may benefit older patients with metastatic breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B386dfc38-b4d6-4888-af01-4b1962389fb6%7D/cdk46-inhibitors-may-benefit-older-patients-with-metastatic-breast-cancer

Dec 21st, 2017 - Patients with breast cancer aged 70 years or older tolerated treatment with CDK4/6 inhibitor therapy, according to results of a retrospective pooled analysis conducted by the FDA and presented at the San Antonio Breast Cancer Symposium.

CDK4/6 inhibitors have similar efficacy in older breast cancer patients
https://www.mdedge.com/oncologypractice/article/154212/breast-cancer/cdk4/6-inhibitors-have-similar-efficacy-older-breast

Dec 12th, 2017 - Treatment with CDK4/6 inhibitors appears to have the same efficacy in older breast cancer patients, as compared with younger ones.

Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer
http://www.ascopost.com/News/58336

Dec 8th, 2017 - Among patients with hormone receptor–positive HER2-negative stage II–III breast cancer without clinical evidence of recurrence, those who had circulating tumor cells (CTCs) detected in blood 5 years after diagnosis had an increased risk for late recurrence of breast cancer, according to data presented by Sparano et al at the 2017 San Antonio Breast Cancer Symposium (Abstract GS6-03).

Circulating Tumor Cells May Predict Late Recurrence in Hormone Receptor–Positive Breast Cancer
http://www.ascopost.com/issues/january-25-2018/circulating-tumor-cells-may-predict-late-recurrence-in-hormone-receptor-positive-breast-cancer/

Jan 25th, 2018 - In patients with early breast cancer, the presence in the blood of circulating tumor cells 5 years after diagnosis increases the risk for recurrence nearly 20-fold, researchers reported at the 2017 San Antonio Breast Cancer Symposium.

Combined Residual Risk Score Test and Predicting Breast Cancer Risk in Women Who Tested Negative for Hereditary Mutations
http://www.ascopost.com/News/58334

Dec 8th, 2017 - Results from a validation study to better define the risk of breast cancer in women of European ancestry who tested negative for a hereditary cancer mutation with a hereditary cancer risk test (myRisk Hereditary Cancer test) were reported earlier this week in a spotlight presentation at the 2017 San Antonio Breast Cancer Symposium (Abstract PD1-08).

Combination of Pembrolizumab and Trastuzumab Shows Early Promise for Patients With Trastuzumab-Resistant Breast Cancer
http://www.ascopost.com/News/58327

Dec 7th, 2017 - A combination of pembrolizumab (Keytruda) and trastuzumab (Herceptin) tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab, according to data presented from the phase Ib/II PANACEA trial by Loi et al at the 2017 San Antonio Breast Cancer Symposium (A...